Home › Karsinoma ng Nasopharynx
Pag-aaral pangklinika para sa Karsinoma ng Nasopharynx na nagre-recruit sa U.S.
13 pag-aaral para sa Karsinoma ng Nasopharynx ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Atlanta, GA6 pag-aaral
- Chicago, IL3 pag-aaral
- Cincinnati, OH3 pag-aaral
- Richmond, VA3 pag-aaral
- Los Angeles, CA3 pag-aaral
- Charlotte, NC3 pag-aaral
- Pittsburgh, PA3 pag-aaral
- Washington, DC3 pag-aaral
- San Francisco, CA3 pag-aaral
- Milwaukee, WI3 pag-aaral
- Oklahoma City, OK3 pag-aaral
- Houston, TX3 pag-aaral
Ayos sa estado
- California6 pag-aaral
- Georgia6 pag-aaral
- Illinois3 pag-aaral
- Maryland3 pag-aaral
- Missouri3 pag-aaral
- North Carolina3 pag-aaral
- Ohio3 pag-aaral
- Oklahoma3 pag-aaral
- Pennsylvania3 pag-aaral
- South Carolina3 pag-aaral
- Texas4 pag-aaral
- Virginia4 pag-aaral
- Wisconsin3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06479811Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Nagre-recruitPhase 2
Hanggang edad 21 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06064097Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06532279A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07749586Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 15, 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT06682442Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT03010150TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 4, 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 11, 2026 · NCT06636734Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.